CNS Programs

nLife Therapeutics is developing the delivery platform in the following disease areas:

  • Parkinson’s Disease (PD) through the development of a First in Class Disease modifying Therapy To Selectively Silence Alpha-Synuclein In monoaminergic neurons  stopping the toxic alpha-synuclein accumulation.
  • Huntington’s Disease (HD) by reducing the level of altered Htt in striatal and cortical neurons stopping the disease progression.